Fidmi Medical Launches U.S. Sales of Novel Low-Profile PEG Device and Raises $2.2 Million

Fidmi Medical Ltd. has announced completion of a $2.2 million financing round and launched its FDA-cleared low-profile Percutaneous Endoscopic Gastrostomy (PEG) device in the U.S. Investors in the round include leading medical technology company Micro-Tech (Nanjing) Co., Ltd. (688029: Shanghai), The Trendlines Group (SGX: 42T) (OTCQX: TRNLY), and Agriline. Micro-Tech has been named Fidmi’s exclusive distributor in the U.S. and China.

Gastrostomy tubes, which help patients receive long-term nutritional support, are typically placed endoscopically and are replaced every 3-6 months. Complications such as clogging and dislodgement are common, resulting in inadequate nutrition and medication delivery, numerous tube replacements, and hospitalizations, all at substantial cost to patients and the health care system.

Within this $800 million market, Fidmi Medical’s innovative low-profile gastrostomy system can be utilized for both initial placement and replacement and is more durable and comfortable for patients. Fidmi’s improved low-profile gastrostomy tube has a replaceable inner tube that can easily be changed by patients without the assistance of medical professionals and a highly stable internal bumper that is resistant to accidental dislodgement. These features are expected to result in fewer complications, reducing healthcare costs for payers and healthcare systems. The Fidmi PEGs will provide a substantial improvement in quality of life for patients and their caregivers.

Fidmi Medical CEO Shahar Millis remarked, “We are truly excited to embark on the market entry phase for Fidmi. With FDA clearance and strategic collaboration with Micro-Tech, a leader in this field, we are well-positioned to make a real difference for people requiring long-term nutritional support.”

“Together, we saw the opportunity to distribute a device that positively impacts patients and helps them get back to living their lives. We worked quickly to align on a distribution plan that allows the system to be accessible by more physicians — meeting their needs for more efficient and higher quality patient care, all while tangibly reducing the cost,” said Chris Li, President of Micro-Tech Endoscopy USA. “We are proud to partner with Fidmi and applaud their success in improving patient quality of life.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy